Publications & Presentations



Peer Reviewed Publications

A list of selected articles authored by EEU Researchers that have been published in peer reviewed journals.
  1. Ellis AK, Saha T, Arellano R, Zajac A, Payne DM. Successful Management of Cold-Induced Urticaria During Hypothermic Circulatory Arrest. Ann Thoracic Surg 2013; in press.
  2. Ellis AK, Zhu Y, Steacy LM, Walker T and Day JH. A Four-Way, Double-Blind, Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of Azelastine Nasal Spray, versus Loratadine, and Cetirizine in Adult Subjects with Allergen-Induced Seasonal Allergic Rhinitis. Allergy Asthma Clin Immunol 2013 9:16.
  3. Sawicki J, Ellis AK. Stevens-Johnson Syndrome – A review of 14 Adult Cases with One Fatal Outcome. Ann Allergy Asthma Immunol 2013; 110(3): 207-209
  4. Ellis AK. Environmental Exposure Units for Specific Immunotherapy Trials. Proceedings of the 13th International Paul Ehrlich Seminar on Allergen Products for Diagnosis and Therapy: Regulation and Science. Arbeiten au dem Paul-Ehrlich-Institut. In press.
  5. Lakhani N, North ML, Ellis AK. Clinical Manifestations of Allergic Rhinitis. Journal of Allergy & Therapy 2012 S5: 007.
  6. Smith LM, Brassard P, Kwong J, Deeks S, Ellis AK, Lévesque LE. Factors Associated with Uptake and Series Completion of the Quadrivalent Human Papillomavirus Vaccine in an Ontario Cohort of Grade 8 Girls. BMC Public Health 2011; 3(11): 645
  7. North ML, Ellis AK. The role of epigenetics in the developmental origins of allergic disease. Ann Allergy Asthma Immunol 2011; 106(5): 355-61.
  8. Ellis AK, Ratz JD, Day A, Day JH. Factors Affecting the Allergic Rhinitis Response to Ragweed Allergen Exposure. Ann Allergy Asthma Immunol 2010; 104(4): 293-8.
  9. Ellis AK, Ackerman SJ, Crawford L, Du J, Bedi R, Denburg JA. Cord blood molecular biomarkers of eosinophilopoiesis: kinetic analysis of GATA-1, MBP1 and IL-5Rα mRNA expression. Pediatr Allergy Immunol 2010; 21(4 Pt 1): 640-8
  10. Ellis, AK. Biphasic Anaphylaxis: A review of the incidence, characteristics, and predictors. The Open Allergy Journal 2010; 3: 24-28.
  11. Gauvreau G, Ellis AK, Denburg JA. Hemopoietic processes in allergic disease: eosinophil/basophil development. Clin Exp Allergy 2009; 39(9): 1297-306.
  12. JH, Briscoe MP, Ratz, JD, Ellis AK, Yao R, Danzig M. Onset of action of loratadine/montelukast in seasonal allergic rhinitis subjects exposed to ragweed pollen in the Environmental Exposure Unit. Allergy Asthma Proc 2009; 30(3): 270-276.
  13. Denburg JA, Fernandes R, Ellis AK, Cyr M, Crawford L, Kusel M, Holt K, Holt B, Kebadze T, Johnston SL, Sly P, Prescott S, Holt PG. Eosinophil progenitors at birth: intimations of future atopy and inflammation. Allergy Clin Immunol Int: J World Allergy Org, Supplement 2 (2007), 29-31.
  14. Ellis AK, Day JH. Incidence and characteristics of biphasic anaphylaxis: a prospective evaluation of 103 patients. Ann Allergy Asthma Immunol. 2007; 98(1): 64-9.
  15. Ellis AK, Keith PK. Nonallergic rhinitis with eosinophilia syndrome and related disorders. Clin Allergy Immunol. 2007; 19: 87-100.
  16. Ellis AK, Keith PK. Non-allergic rhinitis with eosinophilia syndrome. Current Allergy and Asthma Reports. 2006 May; 6(3): 215-20.
  17. JH, Ellis AK, Rafeiro E, Ratz JD, Briscoe MP. Experimental Models for the Evaluation of Treatment of Allergic Rhinitis. Annals of Allergy, Asthma and Immunology 2006; 96(2): 263-278.
  18. Ellis AK, Day JH. Clinical reactivity to insect stings. Curr Opin Allergy Clin Immunol 2005; 5: 349-54.
  19. Day JH, Briscoe MP, Rafeiro E, Ratz JD, Ellis AK, Frankish CW, Chapman D, deGuia EC, Kramer B, Warner C. Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours post-dose, in the Environmental Exposure Unit. Allergy Asthma Proc 2005; 26(4): 275-82.
  20. Day JH, Ellis AK, Rafeiro E. Levocetirizine: A new selective H1 receptor antagonist for use in allergic disorders. Drugs of Today 2004; 40(5): 415-21.
  21. Ellis AK, Day JH. Anaphylaxis treatment: the details. Can Med Assoc J 2003; 169: 1148-9.
  22. Ellis AK, Day JH. Diagnosis and management of anaphylaxis. Can Med Assoc J 2003; 169(4): 307-12.
  23. Ellis AK, Day, JH. Questions and answers about anaphylaxis. An information sheet for patients. Can Med Assoc J 2003; 169(4): 312.
  24. Wilken JA, Kane RL, Ellis AK, Rafeiro E, Briscoe MP, Sullivan CL, Day JH. A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91(4): 375-85.
  25. Ellis AK, Day JH. The role of epinephrine in the treatment of anaphylaxis. Curr Allergy Asthma Rep 2003; 3(1): 11-4.
  26. Ellis AK, Rafeiro E, Day JH. Quality of life indices may be predictive of placebo and medication response to treatment for allergic rhinitis. Ann Asthma Allergy Immunol 2001; 86(4): 393-6.
  27. Ellis AK, Verma S. Quality of life in women with UTI’s: is “benign” disease a misnomer? J Am Board Fam Practice 2000; 13(6): 392-7.
  28. Day JH, Briscoe MP, Rafeiro E, Ellis AK, Petterson E, Akerlund A. Onset of action of intranasal budesonide (Rhinocort Aqua) in seasonal allergic rhinitis studied in a controlled exposure model. J Allergy Clin Immunol 2000 105(3): 489-94.
  29. Ellis AK, Day JH, Lundie MJ. Impact on Quality of Life in an Allergen Challenge Research Trial. Ann Allergy Asthma Immunol 1999; 83: 33-39.
  30. Day JH, Briscoe MP, Welsh A, Smith JN, Clark AJ, Ellis AK, and Mason J. Onset of action, efficacy, and safety of a single dose of fexofenadine HCl for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997; 79(6): 533-40.
  31. Day JH, Briscoe MP, Clark RH, Ellis AK, and Gervais P. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79(2): 163-72.
  32. CME Review Article – The EEU model is presented to the international allergy community.Day, J.H. and Briscoe, M.P. The Environmental Exposure Unit. A system to test anti-allergic treatment.Ann Allergy Asthma Immunol (1999) 83: 83-93Article Abstract
  33. Impact on quality of life during an allergen challenge research trial.Ellis, A.K., Day, J.H. and Lundie, M.J. Ann Allergy Asthma Immunol (1999) 83: 33-39.Article Abstract
  34. Response to a Letter to the Editor: Outcomes of loratadine efficacy for SAR during environmental exposure.Day, J.HJ Allergy Clin Immunol. (1999) 103: 715.Full Text Response.
  35. Cetirizine, loratadine or placebo in subjects with seasonal allergic rhinitis: Effects after controlled ragweed pollen challenge in an Environmental Exposure Unit.Day, J.H., Briscoe, M.P. and Widlitz, M.J Allergy Clin Immunol. (1998) 101: 638-645.Article Abstract. Article in PDF
  36. Onset of action, efficacy and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an Environmental Exposure Unit.Day, J.H., Briscoe, M.P., Welsh, A.C., Smith, J.N., Clark, A., Ellis, A.K. and Mason, J.Ann Allergy Asthma Immunol. (1997) 79: 533-540.Article Abstract.
  37. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis.Day, J.H., Briscoe, M. P., Clark, R.H., Ellis, A.K. and Gervais, P.Ann. Allergy Asthma Immunol. (1997) 79: 163-172.Article Abstract.
  38. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure.Donovan, J.P., Buckeridge, D.L., Briscoe, M.P., Clark, R.H. and Day, J.H.Ann Allergy Asthma Immunol. (1996) 77: 74-80.Article Abstract.
  39. A randomized, placebo-controlled, double-blind, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis.Day, J.H., Briscoe, M.P., Buckeridge, D.L., Clark, R.H., and Phillips, R.J Allergy Clin Immunol. (1996) 97: 1050-1057.Article Abstract. Article in PDF.

International Presentations

Introducing the EEU to the world…

Since 1995, Dr. James H. Day, the driving force behind the EEU and its continued development as a model for allergy research, has given over 90 presentations to the scientific and medical communities around the world. Below is a selection of those international presentations, lectures and seminars:

  1. “The Environmental Exposure Unit – A method of evaluating anti-allergic treatment.”Paris, France 21 Oct 1999 and Mont Pellier, France 30 Oct 1999.
  2. “The Environmental Exposure Unit: A method to test anti-allergic medication.”8th Biennial Allergy Abroad: Faculty Exchange between Washington University, Queen’s University, Seville University School of Medicine and Barcelona, Madrid. 13 Sep 1997.
  3. “Efficacy of triamcinolone acetonide in seasonal allergic rhinitis.”New Concepts in the Evaluation and Management of Rhinitis. The Annual Meeting of the European Academy of Allergology and Clinical Immunology. 29 May – 05 Jun 1997
  4. “Onset of action of nasal corticosteroids and of four H1 specific antagonists using controlled antigen exposure.”7th Biennial Allergy Abroad: Faculty Exchange between Washington University, Queen’s University, Montpellier University, University of Vienna and Ilaynal Imre University of Health Science. Prague. 09 Oct 1995.
  5. “Controlled Antigen Exposure – A means to assess effectiveness of anti-allergic medication.”Joint International Symposium: New Trends in Allergy IV together with Environmental Allergy and Allergotoxicity III. Hamburg, Germany. 27 Apr – 01 May 1995.
  6. “Comparison of onset of action and efficacy of cetirizine, terfenadine, loratadine, and astemizole as tested by controlled antigen challenge in an Environmental Exposure Unit.”Plenary Session, New York Museum of Natural History. 01 Mar 1995.

Poster Presentations

Abstracts, Posters and other presentation material authored by the EEU. You may request a copy of this material by clicking Request Document in the menu on the left side of this page.
  1. Day, J.H., Briscoe, M.P. and Lorber, R. Onset of action (OA) and efficacy of loratadine (LOR) vs placebo (P) in seasonal allergic rhinitis (SAR) subjects utilizing an Environmental Exposure Unit (EEU). (abstract #1014). J Allergy Clin Immunol. (1998) 101: S245.